NovoCure (NVCR) director sells 2,945 shares to cover RSU tax withholding

Rhea-AI Filing Summary

NovoCure Ltd director Timothy J. Scannell reported an open-market sale of 2,945 Ordinary Shares on June 2, 2026 at a weighted average price of $15.7707 per share. According to the disclosure, these shares were sold to cover tax withholding obligations triggered by the vesting of Restricted Stock Units under NovoCure’s equity incentive plans, and the transaction was mandated by a “sell to cover” provision rather than being a discretionary trade. After this sale, Scannell directly holds 14,288 Ordinary Shares of NovoCure.

Insider Trade Summary

Net Seller: 2,945 shares ($46,445)

Net Sell 1 txn

Insider Scannell Timothy J

Role null

Sold 2,945 shs ($46K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	2,945	$15.7707	$46K

Holdings After Transaction: Ordinary Shares — 14,288 shares (Direct, null)

Footnotes (1)

1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price.

Key Figures

Shares sold: 2,945 shares Weighted average sale price: $15.7707 per share Post-transaction holdings: 14,288 shares +1 more

4 metrics

Shares sold 2,945 shares Ordinary Shares sold on June 2, 2026

Weighted average sale price $15.7707 per share Open-market sale to cover tax withholding

Post-transaction holdings 14,288 shares Ordinary Shares directly owned after the sale

Trade price range $15.65–$15.88 per share Multiple trades within the reported transaction

Key Terms

Restricted Stock Units, sell to cover, equity incentive plans, weighted average sale price

4 terms

Restricted Stock Units financial

"in connection with the vesting of Restricted Stock Units. This sale is mandated"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"tax withholding obligations to be funded by a "sell to cover" transaction"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

equity incentive plans financial

"mandated by the issuer's award agreement under its equity incentive plans"

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

weighted average sale price financial

"prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scannell Timothy J

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/02/2026		S		2,945(1)	D	$15.7707(2)	14,288	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

2. This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price.

Remarks:

	Steven Robbins, as attorney in fact for Scannell, Timothy J.	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did NovoCure (NVCR) director Timothy J. Scannell report?

Timothy J. Scannell reported selling 2,945 NovoCure Ordinary Shares. The sale occurred on June 2, 2026 at a weighted average price of $15.7707 per share, as disclosed in a Form 4 insider trading report.

Why did NovoCure (NVCR) director Timothy J. Scannell sell 2,945 shares?

The 2,945 shares were sold to cover tax withholding obligations from vesting Restricted Stock Units. The filing states the company’s equity incentive plans mandate a “sell to cover” transaction, so the sale was not a discretionary trade by Scannell.

At what price did NovoCure (NVCR) shares sell in Timothy Scannell’s Form 4 transaction?

The reported weighted average sale price was $15.7707 per NovoCure share. A footnote explains the transaction executed in multiple trades, with prices ranging from $15.65 to $15.88, resulting in the disclosed weighted average.

How many NovoCure (NVCR) shares does Timothy J. Scannell hold after the Form 4 sale?

Following the tax-related sale, Timothy J. Scannell directly holds 14,288 NovoCure Ordinary Shares. This remaining stake is reported in the Form 4 as the total number of shares beneficially owned after the covered transaction.

Was Timothy J. Scannell’s NovoCure (NVCR) share sale a discretionary insider trade?

The filing describes the sale as non-discretionary, mandated by NovoCure’s award agreement. Shares were sold under a “sell to cover” provision to fund tax withholding on Restricted Stock Units, rather than reflecting an elective open-market decision.